<DOC>
	<DOCNO>NCT00050882</DOCNO>
	<brief_summary>This study intend evaluate potential relieve symptom associate gastroparesis 12 week treatment oral tablet give twice day GM-611 5mg , 10mg placebo type I II diabetic require insulin . Additionally study evaluate safety tolerability GM-611 compare placebo , level GM-611 blood , possible effect GM-611 diabetic control .</brief_summary>
	<brief_title>Safety Effectiveness Investigational Agent ( GM-611 ) Patients With Diabetic Gastroparesis</brief_title>
	<detailed_description />
	<mesh_term>Gastroparesis</mesh_term>
	<criteria>Major Inclusion Criteria – Others Stipulated within Protocol The study physician must assure have/are : Must least 18 year age diabetes mellitus require insulin , may addition oral antidiabetic agent . At least three month history symptom gastroparesis may include : early satiety ( feel full soon begin meal ) , persistent fullness ( long eating ) , abdominal distention bloating , nausea vomit . No evidence mechanical gastric obstruction , gastric problem since onset gastroparesis symptom . You may require go Gastric Emptying Test ( GET ) procedure . You must willing able maintain daily telephone diary consent participate study . Major Exclusion Criteria – Others Stipulated within Protocol The study physician must assure have/are : Prior history gastric surgery , exclude reflux surgery . Inability withdraw current prokinetic agent ( e.g. , metoclopramide , erythromycin , others ) prior , study . Unstable current medical surgical condition , recent history frequent hospitalization . A history : HIV , recur infection affect gastrointestinal track , cirrhosis , acute chronic liver disease , active pancreatitis , cholecystitis , psychosis , severe depression , Parkinson ’ disease , myopathy , scleroderma , eat disorder , organ transplant . Evidence history QTprolongation , use drug , may associate QTprolongation prohibit . May pregnant , breastfeed use approve method contraception . An allergy intolerance macrolide antibiotic ( e.g. , erythromycin ) . Use investigational drug within 30 day prior screen .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2004</verification_date>
	<keyword>GM-611</keyword>
	<keyword>Diabetic gastroparesis</keyword>
	<keyword>Bloating</keyword>
	<keyword>Delayed gastric empty</keyword>
	<keyword>Mitemcinal</keyword>
</DOC>